Escaping the New Wilderness of Mirrors
In: International journal of intelligence and counterintelligence, Band 22, Heft 4, S. 730-738
ISSN: 1521-0561
14 Ergebnisse
Sortierung:
In: International journal of intelligence and counterintelligence, Band 22, Heft 4, S. 730-738
ISSN: 1521-0561
In: Parameters: the US Army War College quarterly, Band 19, Heft 1
ISSN: 2158-2106
In: Parameters: journal of the US Army War College, Band 19, Heft 3, S. 13
ISSN: 0031-1723
In: Strategic review: a quarterly publication of the United States Strategic Institute, Band 16, Heft 3, S. 34-42
ISSN: 0091-6846
World Affairs Online
In: International journal of intelligence and counterintelligence, Band 1, Heft 2, S. 1-28
ISSN: 1521-0561
In: Armed forces journal international, Band 123, Heft 12, S. 96-100
ISSN: 0196-3597
World Affairs Online
In: Institutions, Institutional Change and Economic Performance in Emerging Markets, S. 109-141
Cybersecurity for the production of safe and effective biopharmaceuticals requires the attention of multiple stakeholders, including industry, governments, and healthcare providers. Cyberbiosecurity breaches could directly impact patients, from compromised data privacy to disruptions in production that jeopardize global pandemic response. Maintaining cybersecurity in the modern economy, where advanced manufacturing technologies and digital strategies are becoming the norm, is a significant challenge. Here, we highlight vulnerabilities in present and future biomanufacturing paradigms given the dependence of this industry sector on proprietary intellectual property, cyber-physical systems, and government-regulated production environments, as well as movement toward advanced manufacturing models. Specifically, we (1) present an analysis of digital information flow in a typical biopharmaceutical manufacturing value chain; (2) consider the potential cyberbiosecurity risks that might emerge from advanced manufacturing models such as continuous and distributed systems; and (3) provide recommendations for risk mitigation. While advanced manufacturing models hold the potential for reducing costs and increasing access to more personalized therapies, the evolving landscape of the biopharmaceutical enterprise has led to growing concerns over potential cyber attacks. Gaining better foresight on potential risks is key for implementing proactive defensive principles, framing new developments, and establishing a permanent security culture that adapts to new challenges while maintaining the transparency required for regulated production of safe and effective medicines.
BASE
In: Harvard Business School BGIE Unit Case No. 112-035
SSRN
Working paper
In: Harvard Business School General Management Unit Case No. 312-095
SSRN
Working paper
SSRN
Working paper
SSRN
Working paper
In: International journal of intelligence and counterintelligence, Band 1, Heft 4, S. 141-144
ISSN: 1521-0561
In: Politische Vierteljahresschrift: PVS : German political science quarterly, Band 49, Heft 2, S. 283-309
ISSN: 0032-3470